Clinical Trials Directory

Trials / Completed

CompletedNCT00347373

Effect of Conjugated Linoleic Acid Supplement on Body Composition

Conjugated Linoleic Acid and Body Fat Mass in Obese Humans

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (planned)
Sponsor
University of North Carolina · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this clinical trial is to examine the effects of a low and high dose of conjugated linoleic acid supplement on body composition in obese humans. Individuals with a body mass index between 30 and 35kg/m2 are randomized to receive either placebo, 3.2gCLA, or 6.4g CLA daily for twelve weeks. Changes in body composition, weight, and clinical laboratory values are compared between the three groups.

Detailed description

Sixty healthy obese adult volunteers will be enrolled and randomized into either: 1) placebo, 2) 3.2 g CLA, or 3) 6.4 g CLA groups and supplemented for 12 weeks. Body fat mass (BFM) and lean body mass will be determined by DEXA at baseline and twelve weeks during the intervention. In addition, indirect calorimetry will be performed at baseline and twelve weeks to measure changes in energy expenditure. The effect of CLA supplementation on weight, waist and hip measurements, and BMI will also be determined at 12 weeks. Plasma CLA and pill counts will be measured as an indication of compliance. Several blood parameters will be monitored throughout the study, and five random 24-hour recall surveys will be used to monitor dietary intake of CLA-rich foods, energy, micronutrients and antioxidants.

Conditions

Interventions

TypeNameDescription
DRUGTonalin Conjugated linoleic acid (dietary supplement)

Timeline

Start date
2004-08-01
Completion
2005-09-01
First posted
2006-07-04
Last updated
2006-07-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00347373. Inclusion in this directory is not an endorsement.